Aktuell 03 Apr 2024 Nouscom erhält weitere Mittel für Krebsimpfstoffe Nouscom hat eine Investition in der Höhe von 7 Millionen Euro von der italienischen Risikokapitalfirma Angelini Ventures erhalten. Damit kann das...
News 03 Apr 2024 Nouscom receives additional funding for cancer vaccines Nouscom has received an investment totalling 7 million euros from the Italian venture capital firm Angelini Ventures. The Basel-based biotech com...
News 26 Mar 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
SWISS Pavilion SWISS Pavilion @ GITEX Technology Week 2024 14 Ott 2024–18 Ott 2024 Emirati Arabi Uniti
Actualités 26 Mar 2024 Les Grands Titres de Suisse occidentale (Mars 2024) D’approches innovantes en matière de soins cardiaques et de plastiques durables à l’amélioration des thérapies pour les lésions de la moelle épin...
SWISS Pavilion SWISS Pavilion @ GITEX Technology Week 2024 14 Ott 2024–18 Ott 2024 Emirati Arabi Uniti
SWISS Pavilion SWISS Pavilion @ GITEX Technology Week 2024 14 Ott 2024–18 Ott 2024 Emirati Arabi Uniti
Aktuell 15 Nov 2023 Nouscom erhält 67,5 Millionen Euro Finanzierung Nouscom hat bei einer Serie C-Finanzierung 67,5 Millionen Euro eingenommen. Das Unternehmen aus Basel will damit die klinische Entwicklung seines...
News 13 Dic 2023 Macrogen establishes foothold in Basel Macrogen Europe is set to move into the Novartis Campus of Switzerland Innovation Park Basel Area. As with its parent company, the South Korean b...
News 15 Nov 2023 Nouscom secures 67.5 million euros in financing Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based company intends to use the funds to advance the clinical dev...
Fact Sheet 16 Feb 2023 The Triman Logo in France The French Decree No. 2014-1577 has made it mandatory from 1 January 2015 to print the Triman Logo on recyclable products and packaging sold to c...
ニュース 02 Giu 2023 欧州のバイオテクノロジー企業の20%がスイスに本社を置いていることが判明 Press release IQVIAが実施し、このほど発表された「2023スイスバイオテックレポート」によると、欧州のバイオテクノロジー企業の20%がスイスに本社を置いていることが明らかになりました。さらに、スイス連邦政府、州、地域による投資促進に関する昨年の統計でも、この傾向が続いていることが確認されています。
News 19 Set 2023 Multiwave Technologies secures CHF 3.8 million for its light portable MRI device An innovator in the realm of medical imaging, Geneva-based deeptech start-up Multiwave Technologies has secured CHF 3.8 million in a dual-phase c...
Fiches d’information 10 Ott 2023 Le logo Triman en France Entré en vigueur le 1er janvier 2015, le décret français n° 2014-1577 rend obligatoire l’impression du logo «Triman» sur les produits et emballag...
Aktuell 02 Giu 2023 Neuste Forschung zeigt, dass 20% der europäischen Biotechs ihren Hauptsitz in der Schweiz haben Press release Neue Untersuchungen von IQVIA, die kürzlich im Swiss Biotech Report 2023 veröffentlicht wurden, zeigen, dass mittlerweile 20% der europäischen Bi...
Actualités 19 Set 2023 Multiwave Technologies lève CHF 3.8 millions pour son dispositif d’IRM portatif Spécialisée dans le domaine de l'imagerie médicale, la start-up deeptech genevoise Multiwave Technologies a levé CHF 3.8 millions lors d'une doub...
News 24 Ago 2023 Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking Drawing from the achievements of its parent company, Nanobacterie, Valais-based AlphaOnco Swiss stands at the forefront of innovative nanomedicin...